Psoriasis is considered one of the most persistent and unpredictable autoimmune diseases. In this disease, the skin cells are known to regenerate ten times faster than the normal level. Due to this, when the regenerated skin cells migrate from the lower layer to the top layers, the increased volume leads to the formation of red plaques with white scales. Plaque psoriasis is the most common type observed and typically occurs on knees, elbows, lower back, and scalp. The plaques formed are itchy and very painful and tend to bleed if they crack.
2% to 3% of the population is affected by psoriasis. However, the percentage increases to 15% to 25% if moderate conditions are also considered. For the treatment of this disease, Novartis pharmaceuticals introduced a biologic drug secukinumab (Cosentyx) which is a fully human monoclonal antibody that reduced the disease by inhibiting the pro-inflammatory cytokine interleukin-17A. The US Food and Drug Administration (FDA) approved this drug through a unanimous 7 to 0 vote.
Used by patients suffering from moderate to severe plaque psoriasis, this is prescribed for either systemic therapy or phototherapy. It can be administered into the patients through the subcutaneous route in one of the three modes of administration: a liquid formulation using either an auto-injector pen or a prefilled syringe and a lyophilized formulation which helps in reconstitution.
Cosentyx was launched in January 2015, and it stands to be the only approved inhibitor of the cytokine interleukin-17A, used in the treatment of diseases like ankylosing spondylitis, psoriatic arthritis, and psoriasis. It is known to be capable of delivering clear or almost clear skin which lasts long. The safety and sustainability of Cosentyx have been proved through their phase studies, and it also offers convenient administration with the help of an auto-injector and is prescribed to be taken only once in a month after specific dosages. Cosentyx helps in the treatment of plaque psoriasis in more than 75 countries across the world.